Wall Street analysts are constantly evaluating companies and adjusting their ratings and price targets based on their latest research and market insights. Here’s a snapshot of some of the most recent changes affecting major publicly traded companies.
Atossa Therapeutics (ATOS)
received a boost from Ascendiant Capital, which raised its price target from $6.25 to $6.50. Analyst Edward Woo maintained a Buy rating, indicating positive sentiment towards the company’s future prospects. Atossa Therapeutics shares closed 7.4% higher on Tuesday, reflecting the market’s reaction to this news.Novartis AG (NVS)
experienced a downgrade from B of A Securities, with analyst Graham Perry lowering the price target from $135 to $130 and shifting the rating from Buy to Neutral. This suggests a more cautious stance on the company’s potential for growth. Novartis shares closed down 0.2% on Tuesday.Camden National Corporation (CAC)
saw its price target increased from $40 to $41 by Keefe, Bruyette & Woods, though analyst Damon Delmonte maintained a Market Perform rating. While this indicates a positive outlook, the Market Perform rating suggests the stock is expected to perform in line with the overall market. Camden National shares closed down 0.3% on Tuesday.Supernus Pharmaceuticals, Inc. (SUPN)
faced a downgrade from Piper Sandler, which cut the price target from $41 to $36 and changed the rating from Overweight to Neutral. This indicates a less optimistic view of the company’s performance going forward. Supernus Pharmaceuticals shares closed down 1.2% on Tuesday.AppLovin Corporation (APP)
received a positive outlook from B of A Securities, which increased the price target from $100 to $120. Analyst Omar Dessouky maintained a Buy rating, expressing confidence in the company’s future performance. Despite this, AppLovin shares closed down 0.1% on Tuesday.Krystal Biotech, Inc. (KRYS)
saw a boost from Stifel, which raised the price target from $204 to $220 while maintaining a Buy rating. This suggests a strong belief in the company’s growth potential. Krystal Biotech shares closed down 1.4% on Tuesday.Dave & Buster’s Entertainment, Inc. (PLAY)
was downgraded by BMO Capital, which cut the price target from $65 to $55 but maintained an Outperform rating. This suggests a less optimistic outlook but still believes the company will outperform the market. Dave & Buster’s shares closed down 0.8% on Tuesday.GameStop Corp. (GME)
experienced a price target reduction from Wedbush, which lowered it from $11 to $10. Analyst Michael Pachter maintained an Underperform rating, reflecting a negative outlook for the company. GameStop shares closed down 3.3% on Tuesday.Academy Sports and Outdoors, Inc. (ASO)
received a positive outlook from Truist Securities, which raised the price target from $60 to $63 and maintained a Buy rating. This signifies a strong belief in the company’s potential for growth. Academy Sports shares closed up 5.2% on Tuesday.Domino’s Pizza, Inc. (DPZ)
saw its price target reduced by BMO Capital, which lowered it from $525 to $510 while maintaining an Outperform rating. This indicates a slightly less optimistic view but still believes the company will outperform the market. Domino’s shares closed down 0.8% on Tuesday.These analyst ratings provide valuable insights into the current sentiment surrounding these companies and can be used as a starting point for investors to conduct their own research and make informed decisions about their portfolio.
It’s important to remember that analyst ratings are just one piece of the puzzle when it comes to investment decisions. It’s crucial to consider multiple factors, including fundamental analysis, industry trends, and personal investment goals, before making any decisions.
